Search results for "Respiratory Physiology"

showing 10 items of 363 documents

Long-term variations of arterial stiffness in patients with obesity and obstructive sleep apnea treated with continuous positive airway pressure

2020

BackgroundObstructive sleep apnea (OSA) is associated with cardiovascular co-morbidities and mortality. Arterial stiffness is an independent predictor of cardiovascular risk and mortality, and is influenced by the presence of OSA and related comorbidities. There is a paucity of data regarding long-term evolution of arterial stiffness in CPAP-treated OSA patients. We aimed to prospectively study long term PWV variations and determinants of PWV deterioration.MethodsIn a prospective obese OSA cohort, at time of diagnosis and after several years of follow-up we collected arterial stiffness measured by carotid-femoral pulse wave velocity (PWV), clinical and metabolic parameters, and CPAP adheren…

MalePulmonologyApneaPhysiologymedicine.medical_treatmentBlood PressurePolysomnography030204 cardiovascular system & hematologyVascular Medicine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractStiffnessCohort StudiesMedical ConditionsMathematical and Statistical TechniquesEndocrinology0302 clinical medicineRisk FactorsMedicine and Health SciencesContinuous positive airway pressurePulse wave velocitySleep Apnea Obstructiveeducation.field_of_studyMultidisciplinaryContinuous Positive Airway Pressuremedicine.diagnostic_testPharmaceuticsStatisticsQlongitudinal studyRSleep apneaBlood Pressure Monitoring AmbulatoryMiddle Aged[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthCardiovascular TherapyNeurologyPhysiological ParametersCardiovascular DiseasesPhysical SciencesHypertensioncardiovascular systemCardiologysleep disordered breathing.MedicineFemaleResearch Articlecirculatory and respiratory physiologymedicine.medical_specialtySleep ApneaEndocrine Disorderspulse wave velocityPolysomnographyScienceMaterials ScienceMaterial PropertiesPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioResearch and Analysis MethodsRespiratory Disorders03 medical and health sciencesVascular StiffnessDrug Therapy[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes MellitusmedicineMechanical PropertiesHumansObesityStatistical Methodseducationbusiness.industryBody WeightBiology and Life Sciencesmedicine.diseaserespiratory tract diseasesObstructive sleep apneaBlood pressure030228 respiratory systemMetabolic DisordersMultivariate AnalysisArterial stiffness[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractSleep DisordersbusinessMathematicsPLOS ONE
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Ultra-low tidal volume ventilation-A novel and effective ventilation strategy during experimental cardiopulmonary resuscitation.

2018

Abstract Background The effects of different ventilation strategies during CPR on patient outcomes and lung physiology are still poorly understood. This study compares positive pressure ventilation (IPPV) to passive oxygenation (CPAP) and a novel ultra-low tidal volume ventilation (ULTVV) regimen in an experimental ventricular fibrillation animal model. Study design Prospective randomized controlled trial. Animals 30 male German landrace pigs (16–20 weeks). Methods Ventricular fibrillation was induced in anesthetized and instrumented pigs and the animals were randomized into three groups. Mechanical CPR was initiated and ventilation was either provided by means of standard IPPV (RR: 10/min,…

MaleResuscitationSwinemedicine.medical_treatmentRespiratory physiology030204 cardiovascular system & hematologyEmergency NursingLung injuryAdvanced Cardiac Life SupportReal-Time Polymerase Chain ReactionIntermittent Positive-Pressure Ventilation03 medical and health sciencesRandom Allocation0302 clinical medicinemedicineTidal VolumeAnimalsHumansCardiopulmonary resuscitationTidal volumeAnalysis of VarianceContinuous Positive Airway Pressurebusiness.industryPulmonary Gas Exchange030208 emergency & critical care medicineOxygenationLung Injurymedicine.diseaserespiratory tract diseasesDisease Models AnimalTreatment OutcomeAnesthesiaVentricular fibrillationEmergency MedicineBreathingCardiology and Cardiovascular MedicinebusinessResuscitation
researchProduct

Ejection Fraction by Echocardiography for a Selective Use of Magnetic Resonance After Infarction

2020

[EN] Background Cardiac magnetic resonance (CMR) permits robust risk stratification of discharged ST-segment-elevation myocardial infarction patients, but its indiscriminate use in all cases is not feasible. We evaluated the utility of left ventricular ejection fraction (LVEF) by echocardiography for a selective use of CMR after ST-segment-elevation myocardial infarction. Methods Echocardiography and CMR were performed in 1119 patients discharged for ST-segment-elevation myocardial infarction included in a multicenter registry. The prognostic power of CMR beyond echocardiography-LVEF was assessed using adjusted C statistic, net reclassification improvement index, and integrated discriminati…

MaleRiskmedicine.medical_specialtyVentricular Ejection FractionTime FactorsInfarctionMagnetic Resonance Imaging CineHeart failurePatient ReadmissionVentricular Function LeftTECNOLOGIA ELECTRONICAVentricular Dysfunction LeftPercutaneous Coronary InterventionPredictive Value of TestsInternal medicinemedicineHumansVentricular ejection fractionRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionProspective StudiesRegistriesAgedEjection fractionmedicine.diagnostic_testbusiness.industryReproducibility of ResultsMagnetic resonance imagingStroke VolumeMiddle Agedmedicine.diseasePrognosisNet reclassification improvementMyocardial infarctionTreatment OutcomeEchocardiographyMagnetic resonanceHeart failurecardiovascular systemCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessMacecirculatory and respiratory physiology
researchProduct

Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabet…

2016

Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg …

MaleSettore MED/09 - Medicina InternaAntihypertensive agentsPhysiologyMissed DoseTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyPharmacologyEssential hypertensionlaw.invention0302 clinical medicineDiabetes mellitusRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerDrug CombinationPerindoprilMedicine030212 general & internal medicineAntihypertensive agentTetrazoleImidazolesSettore MED/37 - NeuroradiologiaMiddle AgedCalcium Channel BlockersDrug CombinationsTreatment OutcomeHypertensionFemaleEssential HypertensionOlmesartanCalcium Channel BlockerCardiology and Cardiovascular MedicineType 2circulatory and respiratory physiologymedicine.drugHumanAdultmedicine.medical_specialtyAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineDiabetes mellitumissed dose; hypertension; therapeutic efficacyCombination therapyUrologytherapeutic efficacyNOMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal MedicineHumansOlmesartanAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilImidazolemissed doseAgedbusiness.industryAngiotensin-Converting Enzyme Inhibitormedicine.diseaseAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineBlood pressureDiabetes Mellitus Type 2PerindoprilAmlodipinebusinessAngiotensin II Type 1 Receptor Blockers
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

Global Lung Function Initiative 2012 reference values for spirometry in South Italian children

2017

Rationale Despite the widespread use of the Global Lung Function Initiative (GLI) 2012 reference values, there is still the need of testing their applicability in local areas. Objectives The aims of this study are to evaluate applicability of GLI reference equations in a large population-based sample of normal schoolchildren from Sicily, and to compare GLI and previous prediction equations in terms of spirometry test interpretation. Methods GLI equations were evaluated in 1243 normal schoolchildren, 49% males, aged 7–16 years, height 116–187 cm. Normality assumptions for the GLI z-scores (FEV1, FVC, FEV1/FVC) were tested, and bootstrap confidence intervals for the mean (0 expected) and …

MaleSpirometryPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyPulmonary functionAdolescentmedia_common.quotation_subjectVital CapacityStandard scoreWhite PeoplePulmonary function testing03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineReference ValuesForced Expiratory VolumemedicineHumans030212 general & internal medicineChildLungSicilyNormalityLung functionmedia_commonintegumentary systemmedicine.diagnostic_testbusiness.industryZ-scorerespiratory systemrespiratory tract diseasesAirway ObstructionItaly030228 respiratory systemSpirometryPaediatricReference valuesFemaleBootstrap confidence intervalbusinessReference equationcirculatory and respiratory physiologyDemography
researchProduct

Authors’ response

2012

Claudio Sorino,1,2 Salvatore Battaglia,1 Nicola Scichilone,1 Claudio Pedone,3 Raffaele Antonelli-Incalzi,3 Duane Sherrill,4 Vincenzo Bellia11Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Division of Pulmonology, S Anna Hospital, Como, Italy; 3Chair of Geriatrics, University Campus Bio-Medico, Roma, Italy; 4Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USABackground: The choice between lower limit of normal or fixed value of forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC) &amp;lt; 0.70 as the criterion for confirming airway obstruction is an open issue. In t…

MaleSpirometryVital capacitymedicine.medical_specialtyLetterCross-sectional studyVital CapacityInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioForced Expiratory VolumeInternal medicinemedicineHumansAgedAged 80 and overlcsh:RC705-779COPDmedicine.diagnostic_testbusiness.industryGeneral MedicineHealthy elderlylcsh:Diseases of the respiratory systemAirway obstructionrespiratory systemmedicine.diseaselung function test elderlyRespiratory Function TestsSurgeryrespiratory tract diseasesCross-Sectional StudiesItalyCardiologyFemalebusinesscirculatory and respiratory physiologyInternational Journal of COPD
researchProduct

Pneumocyte Apoptosis Induction during Cardiopulmonary Bypass: Effective Prevention by Radical Scavenging UsingN-Acetylcysteine

2007

Cardiopulmonary bypass (CPB) and cardioplegic arrest are associated with pulmonary dysfunction. We sought to investigate whether pulmonary ischemia/reperfusion during standard CPB and cardioplegic arrest is associated with reactive oxygen species (ROS)-mediated pulmonary tissue injury and pneumocyte apoptosis induction, and whether ROS scavenging using N-acetylcysteine (NAC) attenuates these alterations. Twelve pigs (41 +/- 8 kg) were randomized to receive either NAC (100 mg/kg prior to CPB; n = 7) or placebo (n = 5) and subjected to CPB and 60 min of cold (4 degrees C) crystalloid cardioplegic arrest. We collected lung biopsies prior to CPB, at 60 min CPB, as well as at 30, 60, and 120 min…

MaleSwineApoptosismedicine.disease_causePlacebolaw.inventionAcetylcysteinechemistry.chemical_compoundlawCardiopulmonary bypassAnimalsMedicineLungchemistry.chemical_classificationReactive oxygen speciesCardiopulmonary BypassLungCaspase 3business.industryNitrotyrosineFree Radical ScavengersAcetylcysteinesurgical procedures operativemedicine.anatomical_structurechemistryApoptosisAnesthesiaTyrosineFemaleSurgeryReactive Oxygen SpeciesbusinessOxidative stresscirculatory and respiratory physiologymedicine.drugJournal of Investigative Surgery
researchProduct

Lung function after acute and repeated exposures to extremely cold air (-110 degrees C) during whole-body cryotherapy.

2006

Whole-body cryotherapy (WBC) is one mode of cold therapy, during which rheumatic patients are exposed to very cold air (-110 degrees C) in minimal clothing. It is also proposed to have a bronchodilatory effect. The aim was to examine the effects of WBC on lung function in healthy humans after acute and repeated exposures. Twenty-five healthy, non-smoking subjects participated in the study. They were exposed to WBC for 2 min three times per week for 12 weeks. The peak expiratory flow rate (PEF) and forced expiratory volume in 1 s (FEV1) were measured before and after (at 2 and 30 min) the first WBC, and then similarly at 4, 8 and 12 weeks. At all time points, after 30 min of the WBC the PEF …

MaleTime FactorsPhysiologymedicine.medical_treatmentBronchoconstrictionCryotherapyPeak Expiratory Flow RateCold Therapyhemic and lymphatic diseasesPhysiology (medical)Statistical significanceForced Expiratory VolumemedicineHumansLung functionbusiness.industryWhole body cryotherapyCold airGeneral MedicineMiddle AgedRespiratory Function TestsBronchodilatationCryotherapyAnesthesiaRespiratory Physiological PhenomenaBronchoconstrictionFemalemedicine.symptombusinesscirculatory and respiratory physiologyClinical physiology and functional imaging
researchProduct